Technosphere insulin in the treatment of Type 1 diabetes mellitus: A systematic review and meta-analysis.

AIMS: Conduct a systematic review and meta-analysis comparing Technosphere Insulin and traditional ultra-rapid insulin in T1DM.

METHODS

Researchers conducted a systematic search on databases to identify randomized controlled trials (RCTs) comparing two insulin regimens-TI and RAI -in patients with type 1 diabetes mellitus (T1DM). The outcomes of interest included changes in HbA1c levels, body weight, and rates of overall and severe hypoglycemia.

RESULTS

Four RCTs were included. There was no significant difference between groups on change in HbA1c (MD 0.04; 95 % CI -0.19-0.27; p = 0.74; I2 = 0 %). In terms of body weight change, the TI group exhibited significantly less (MD -1.05; 95 % CI -1.63 to -0.46; p = 0.0005; I2 = 0 %) compared to the RAI group. Adverse events such as overall hypoglycemia (RR -0.97; 95 % CI 0.94-1.01; p = 0.24; I2 = 26 %) and severe hypoglycemia (RR 0.63; 95 % CI 0.46-0.87; p = 0.005; I2 = 0 %), were significantly more frequent in the RAI group.

CONCLUSIONS

The use of Technosphere Insulin (TI) in T1DM patients did not show a difference in HbA1c, suggesting that TI may offer advantages in weight stability and a lower incidence of hypoglycemic events compared to rapid-acting insulin (RAI).